Guidant starts bifurcated stent trial:
This article was originally published in Clinica
Guidant has begun an international clinical study of its Multi-Link Frontier coronary stent system, which is specifically designed to treat atherosclerotic lesions at the site of a bifurcation - ie where one vessel branches from another. The trial, which is being conducted at 15 centres in nine countries, is expected to enrol 100 patients with de novo (previously untreated) or restenotic bifurcation lesions. Around 20% of patients treated for coronary artery disease are treated for bifurcated lesions, the firm notes.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.